SBC Medical received Nasdaq cure notice for board independence rule breach
SBC Medical Group Holdings received written notice on July 10, 2026, from Nasdaq's Listing Qualifications Department that the company no longer complies with Nasdaq independence rules for board and audit committee membership following Mike Sayama's decision not to seek re-election at the July 8 annual meeting. Nasdaq granted a cure period until the earlier of the next annual shareholders' meeting or July 9, 2027 (or January 5, 2027 if the next annual meeting occurs before that date). The company's board currently has four members, two of whom are independent, and the audit committee has two independent directors, below Nasdaq requirements. The company is actively searching for a fifth independent director to restore compliance.
Key facts
- Nasdaq cure period expires July 9, 2027 or at next annual shareholders' meeting, whichever is earlier
- Mike Sayama did not seek re-election at July 8, 2026 annual meeting
- Board currently comprises 4 members with 2 independent directors; needs majority independent
- Audit Committee has 2 independent directors; Nasdaq requires at least 3
- Company intends to appoint fifth independent director to Board and Audit Committee, Nominating and Corporate Governance Committee, and Compensation Committee
Why it matters
The company has until mid-2027 to restore compliance with Nasdaq's independent director rules; failure to do so within the cure period could trigger delisting proceedings, though the company remains listed during the compliance window.
Share
Derived from 8-K filed 2026-07-14. Not investment advice. View the source filing on SEC.gov →